
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Vivos Therapeutics Inc (VVOS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VVOS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $4.22
1 Year Target Price $4.22
1 | Strong Buy |
0 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.65% | Avg. Invested days 24 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.15M USD | Price to earnings Ratio - | 1Y Target Price 4.22 |
Price to earnings Ratio - | 1Y Target Price 4.22 | ||
Volume (30-day avg) 2 | Beta 7 | 52 Weeks Range 1.98 - 7.95 | Updated Date 08/15/2025 |
52 Weeks Range 1.98 - 7.95 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-15 | When - | Estimate -0.385 | Actual - |
Profitability
Profit Margin -76.82% | Operating Margin (TTM) -129.91% |
Management Effectiveness
Return on Assets (TTM) -61.21% | Return on Equity (TTM) -450.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 26207687 | Price to Sales(TTM) 1.86 |
Enterprise Value 26207687 | Price to Sales(TTM) 1.86 | ||
Enterprise Value to Revenue 1.79 | Enterprise Value to EBITDA -0.21 | Shares Outstanding 5889520 | Shares Floating 3818883 |
Shares Outstanding 5889520 | Shares Floating 3818883 | ||
Percent Insiders 32.99 | Percent Institutions 8.93 |
Upturn AI SWOT
Vivos Therapeutics Inc

Company Overview
History and Background
Vivos Therapeutics, Inc. was founded in 2016. It focuses on developing and commercializing innovative technologies and protocols for treating mild-to-moderate obstructive sleep apnea (OSA) and sleep-disordered breathing in adults and children.
Core Business Areas
- Medical Devices: Development and sale of the Vivos System, a non-surgical, non-pharmaceutical treatment modality for OSA and sleep-disordered breathing, including the DNA appliance and mRNA appliance.
- Educational Programs: Providing training and certification programs for dentists to become Vivos-integrated practitioners, enabling them to offer Vivos treatment to their patients.
Leadership and Structure
Kirk Huntsman is the CEO. The company has a board of directors and an executive team overseeing different departments, including sales, marketing, research & development, and clinical operations.
Top Products and Market Share
Key Offerings
- DNA Appliance: A removable oral appliance designed to expand the upper airway, aiming to correct the underlying causes of OSA. Market share data is not publicly available. Competitors: Align Technology (Invisalign) in the broader orthodontic market, but few directly address OSA in the same way. Some overlap with mandibular advancement devices.
- mRNA Appliance: Another removable oral appliance that works similarly to the DNA appliance but is designed for a broader range of patients. Market share data is not publicly available. Competitors: Align Technology (Invisalign), mandibular advancement devices, CPAP machines (ResMed, Philips).
- Vivos Integrated Practice (VIP) program: Educational program to train dentists on the Vivos Method. Number of enrolled practices not public. Competitors: Various continuing education providers in dentistry.
Market Dynamics
Industry Overview
The market for OSA treatment is large and growing, driven by increasing awareness, aging populations, and rising obesity rates. Current treatments include CPAP, oral appliances, and surgery.
Positioning
Vivos positions itself as offering a unique, non-surgical, potentially curative approach to OSA, differentiating itself from traditional symptomatic treatments like CPAP. They focus on addressing the underlying anatomical issues contributing to sleep apnea.
Total Addressable Market (TAM)
The global sleep apnea devices market is estimated at billions of dollars annually. Vivos is positioned to capture a segment of this market by providing a potentially curative therapy.
Upturn SWOT Analysis
Strengths
- Non-surgical, potentially curative treatment for OSA
- Focus on addressing the root cause of OSA
- Proprietary technology and intellectual property
- Growing network of Vivos-trained dentists
- Alternative option to CPAP therapy
Weaknesses
- Limited clinical data compared to established treatments like CPAP
- Reliance on dentist adoption and training
- Higher initial cost compared to some other treatments
- Relatively small company with limited resources
- Dependent on insurance coverage for reimbursement.
Opportunities
- Expanding the network of Vivos-trained dentists
- Increasing awareness among patients and physicians
- Securing insurance coverage for Vivos treatment
- Developing new products and applications for Vivos technology
- Partnering with sleep clinics and other healthcare providers.
Threats
- Competition from established OSA treatments (CPAP, surgery)
- Lack of clinical data supporting the long-term efficacy of Vivos treatment
- Changes in insurance reimbursement policies
- Economic downturn affecting patient affordability
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- RMD
- PRGO
Competitive Landscape
Vivos offers a unique approach that addresses root causes, differentiating it from symptom management. However, it faces significant competition from established players with greater resources and more extensive clinical data.
Growth Trajectory and Initiatives
Historical Growth: Requires analysis of historical financial data. Look for revenue growth trends and key drivers of growth.
Future Projections: Future growth projections are typically based on analyst estimates, which are not available here. However, growth will depend on factors such as adoption by dentists, insurance coverage, and new product development.
Recent Initiatives: Recent Initiatives includes new marketing and education campaigns to increase awareness and dentist adoption.
Summary
Vivos Therapeutics has a novel approach to treating sleep apnea with potential for long-term correction, which differentiates them. Adoption depends on educating dentists and securing insurance coverage, which is a challenge. Competition with giants and limited clinical data are major risks, but successful expansion could yield significant growth. Overall, Vivos is a company with high risk and high potential reward.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party industry reports (where available)
- Analyst reports (where available)
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be limited or incomplete due to access restrictions. Market share estimates are approximate and based on publicly available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vivos Therapeutics Inc
Exchange NASDAQ | Headquaters Littleton, CO, United States | ||
IPO Launch date 2020-12-11 | Co-Founder, Chairman of the Board & CEO Mr. R. Kirk Huntsman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 113 | Website https://www.vivos.com |
Full time employees 113 | Website https://www.vivos.com |
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.